-
Colour and caution as banned kite-flying festival returns to Pakistan
-
England cling on to beat Nepal in last-ball thriller
-
UK foreign office to review pay-off to Epstein-linked US envoy
-
England's Arundell eager to learn from Springbok star Kolbe
-
Czech snowboard great Ledecka fails in bid for third straight Olympic gold
-
Expectation, then stunned silence as Vonn crashes out of Olympics
-
Storm-battered Portugal votes in presidential election run-off
-
Breezy Johnson wins Olympic downhill gold, Vonn crashes out
-
Vonn's Olympic dream cut short by downhill crash
-
French police arrest five over crypto-linked magistrate kidnapping
-
Late Jacks flurry propels England to 184-7 against Nepal
-
Vonn crashes out of Winter Olympics, ending medal dream
-
All-new Ioniq 3 coming in 2026
-
New Twingo e-tech is at the starting line
-
New Ypsilon and Ypsilon hf
-
The Cupra Raval will be launched in 2026
-
New id.Polo comes electric
-
Iran defies US threats to insist on right to enrich uranium
-
Seifert powers New Zealand to their record T20 World Cup chase
-
Naib's fifty lifts Afghanistan to 182-6 against New Zealand
-
Paul Thomas Anderson wins top director prize for 'One Battle After Another'
-
De Beers sale drags in diamond doldrums
-
NFL embraces fashion as league seeks new audiences
-
What's at stake for Indian agriculture in Trump's trade deal?
-
Real Madrid can wait - Siraj's dream night after late T20 call-up
-
Castle's monster night fuels Spurs, Rockets rally to beat Thunder
-
Japan votes in snow-hit snap polls as Takaichi eyes strong mandate
-
Pakistan's capital picks concrete over trees, angering residents
-
Berlin's crumbling 'Russian houses' trapped in bureaucratic limbo
-
Neglected killer: kala-azar disease surges in Kenya
-
Super Bowl set for Patriots-Seahawks showdown as politics swirl
-
Sengun shines as Rockets rally to beat NBA champion Thunder
-
Matsuyama grabs PGA Phoenix Open lead with Hisatsune one back
-
Washington Post CEO out after sweeping job cuts
-
Haiti's transitional council hands power to PM
-
N. Korea to hold party congress in February, first since 2021
-
Thailand votes after three leaders in two years
-
Swiss joy as Von Allmen wins first gold of Winter Olympics
-
George backs England to 'kick on' after Six Nations rout of Wales
-
Malinin upstaged as Japan keep pressure on USA in skating team event
-
Vail's golden comets Vonn and Shiffrin inspire those who follow
-
Veteran French politician loses culture post over Epstein links
-
Japan's Kimura wins Olympic snowboard big air gold
-
Arteta backs confident Gyokeres to hit 'highest level'
-
Hojlund the hero as Napoli snatch late win at Genoa
-
England's Arundell 'frustrated' despite hat-trick in Wales romp
-
Lollobrigida skates to first Italian gold of Winter Olympics on her birthday
-
Arundell hat-trick inspires England thrashing of Wales in Six Nations opener
-
Chile's climate summit chief to lead plastic pollution treaty talks
-
Rosenior hails 'unstoppable' Palmer after treble tames Wolves
DR Congo drug manufacturing plan sparks safety concerns
Sitting at his desk overlooking a pharmaceutical factory floor on the outskirts of the Congolese capital Kinshasa, Joss Ilunga Dijimba, 52, cracked a jovial smile.
"It's not easy doing business in Congo," he said.
His family was forced to relocate the factory in the 1990s to survive bouts of mass looting. And nowadays, there are onerous taxes, customs duties, and problems retaining talented staff.
His company, which employs about 40 people and produces generics such as paracetamol, is one of a tiny number of drug manufacturers in the Democratic Republic of Congo, an impoverished nation roughly the size of Western Europe.
But a government plan to require hospitals and NGOs to buy more locally produced drugs could soon boost the fledgling pharmaceutical industry -- despite fears in some quarters that safety standards are far below international norms.
Several NGOs, some of which provide medical care in the DRC's conflict-torn east, have requested opt-outs.
At the small Pharmagros plant, behind barbed-wire walls near the Congo river, men in hairnets and white coats formulate medicines with imported precursor using lab equipment in airconditioned rooms.
"Promoting local industry's a good thing," said Dijimba, a University of Texas graduate, insisting that several Congolese firms, including his, maintained high standards.
"It could grow the middle class."
About 73 percent of the DRC's population of 90 million lives on under $1.9 a day, according to the World Bank. Most products in the African country are imported.
- 'At your own peril' -
The Congolese government has designated 35 drug molecules, including paracetamol, that medical facilities will be required to purchase in locally made form.
The government wants to stimulate business without banning imports, said Donatien Kabamb Kabey, the pharmaceuticals director at the DRC's health ministry.
He explained that all the molecules can be replaced with imported equivalents, suggesting that ibuprofen could replace paracetamol, for example.
Although not yet implemented, the policy already appears to be working.
Fifteen new pharma businesses are setting up in the DRC ahead of the new rules, Kabey said, which will add to the existing 24.
The policy was partly designed to encourage factories to return after fleeing the country in the 1990s, he added, when unpaid soldiers went on the rampage towards the end of ex-dictator Mobutu Sese Seko's reign.
But experts warn that Congolese-made medicines face a major challenge: reassuring doctors and patients that they meet regulatory standards.
"When you go to the private sector in Congo, you do it at your own peril," said Ed Vreeke, who runs the Belgium-based independent pharmaceutical auditing firm Quamed.
"They know darn well that the quality they produce is not good."
Vreeke said Congolese regulators had improved, but the country lacked the massive resources needed to properly perform audits, check labels, and inspect the chemical composition of drugs for safety.
Kabey, whose department at the health ministry oversees inspections, said standards had improved "enormously" in recent years, but did not provide further details.
He said the government was establishing a national quality-control lab.
- 'A huge thing' -
Shoddy or falsified medicines kill hundreds of thousands of people every year, according to the World Health Organization, mostly in poor countries.
The DRC's hot and humid climate also poses storage problems.
A 2021 study of both imported and locally produced eye drops sold in Kinshasa, for example, showed that three out of the seven products tested were substandard. The one sample manufactured in the DRC was contaminated.
Outside a pharmacy in Kinshasa's upmarket Gombe district, clutching a bag of medicines, 29-year-old corporate lawyer Joelle Mamputu said she didn't pay attention to where drugs were made but said she had "no prejudice".
However, a 52-year-old public servant named Olivier said there was "quite a difference" between Congolese and foreign drugs.
He added he would buy Congolese drugs were the quality the same.
Despite official assurances, major international NGOs such as Doctors Without Borders (MSF) and Medecins du Monde (MDM) have requested opt-outs from the purchasing requirements, several humanitarian workers said.
MSF declined to comment.
MDM confirmed it had asked for an exemption due to concerns over quality and capacity to meet demand.
"It's a huge thing," said one humanitarian who asked for anonymity, explaining that the new rules will affect all non-governmental organisations, hospitals and pharmacies.
Many aid workers understand the need to promote enterprise, he said, but there are internal disagreements about whether to compromise on quality.
"We need to have high quality standards for everyone, but the reality of the country is that sometimes it's impossible".
F.Schneider--AMWN